As a result, we can see that the mutation frequencies of genes such as KDM6A and FGFR3 are significantly enriched in C3 (Figure 4C), where bladder cancers with FGFR3 mutations have been reported to target by the FDA-approved drug Erdafitinib (Loriot et al., 2019), and enzymatic inhibitor of EZH2 (Tazemetostat) has been suggested to target advanced urothelial carcinoma patients with KDM6A mutations (Meeks et al., 2020). This evidence concerns the gene EZH2 and urinary bladder cancer.